Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
2025 · 4th Quarter (Oct 1 - Dec 31)
AVIDITY BIOSCIENCES, INC.
Filed by FEROX STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- FEROX STRATEGIES
- Filing UUID
- 1667fdae-9f86-4c8b-9f5c-a05628b22aa0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.